China’s NMPA Policy to Reduce Time from Drug Approval

added blog Health

2026-01-20 06:33:56 -

China’s pharmaceutical Regulatory landscape continues to evolve rapidly. In December 2025, the National Medical Products Administration (NMPA) introduced a new policy aimed at significantly reducing the time between drug approval and market supply in China. This reform is expected to play a critical role in China’s drug approval and commercialization strategies...

0 Comments 0 Shares 64 Views 0 Reviews